Previous Close | 0.4300 |
Open | 0.5500 |
Bid | 0.3500 |
Ask | 0.4000 |
Strike | 2.00 |
Expire Date | 2024-07-19 |
Day's Range | 0.3500 - 0.5500 |
Contract Range | N/A |
Volume | |
Open Interest | 1.8k |
MALVERN, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the second cohort of its Phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment for life. "The completion of dosing for Cohort 2 p
Discover how Ocugen Inc navigates its financial landscape while pushing boundaries in gene therapy development.